PRELUDE THERAPEUTICS INC(NASDAQ:PRLD) stock News

PRLD Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

2 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

2 months ago - By: Benzinga - Mentions: LUCY WORX SNTI PMCB ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Announces Presentations at 2025 AACR Annual Meeting

3 months ago - By: Prelude Therapeutics, Incorporated

Prelude Announces Presentations at 2025 AACR Annual Meeting

3 months ago - By: Yahoo Finance - Mentions: GOSS DAWN VIR NUVB ...

Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple

4 months ago - By: Benzinga - Mentions: LXRX ME RGC IBO ...

12 Health Care Stocks Moving In Friday's Intraday Session

4 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

4 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

5 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

5 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

7 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

8 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

8 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

9 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

9 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

10 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

10 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

10 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

10 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

11 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

11 months ago - By: Prelude Therapeutics, Incorporated

PRELUDE THERAPEUTICS INC (PRLD) Stock News

PRLD Latest News, Press Relases and Analysis